Envarsus XR

1.1 Prophylaxis of Organ Rejection in De Novo Kidney Transplant Patients

ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants [see Clinical Studies (14.1)].

Prophylaxis of Organ Rejection in Stable Kidney Transplant Patients Converting from Immediate-Release Formulations

ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants [see Clinical Studies (14.2)].

Important Administration Instructions

• ENVARSUS XR (tacrolimus extended-release tablets) is not interchangeable or substitutable with tacrolimus extended-release capsules, tacrolimus capsules, and tacrolimus for oral suspension. Under or overexposure to tacrolimus may result in graft rejection or other serious adverse reactions [see Warnings and Precautions (5.3)]. ENVARSUS XR should not be used without the supervision of a physician with experience in immunosuppressive therapy.
• ENVARSUS XR should be taken on an empty stomach consistently at the same time of the day, preferably in themorning to ensure consistent and maximum possible drug exposure, at least 1 hour before a meal or at least 2 hoursafter a meal [see Clinical Pharmacology (12.3)].
• Advise patients to swallow ENVARSUS XR tablets whole with fluid (preferably water); patients must not chew,divide, crush or dissovle the tablets.
• If a dose is missed, instruct the patient to take it as soon as possible within 15 hours after missing the dose. Beyondthe 15-hour time frame, instruct the patient to wait until the usual scheduled time to take the next regular daily dose.Instruct the patient not to double the next dose.
• Patients should avoid eating grapefruit or drinking grapefruit juice or alcoholic beverage while taking ENVARSUSXR [see Drug Interactions (7.2)].

2.2 Dosing in De Novo Kidney Transplant Patients

The recommended starting dose of ENVARSUS XR in de novo kidney transplant patients is 0.14 mg/kg/day. Titrate ENVARSUS XR dosage based on clinical assessments of rejection and tolerability and to achieve whole blood trough concentration ranges (see Table 1).

Dosing for Conversion from Tacrolimus Immediate-Release Formulations

To convert from a tacrolimus immediate-release product to ENVARSUS XR, administer ENVARSUS XR once daily at adose that is 80% of the total daily dose of the tacrolimus immediate-release product. Monitor tacrolimus whole bloodtrough concentrations and titrate ENVARSUS XR dosage to achieve whole blood trough concentration ranges of 4 to 11ng/mL.

Dosing Adjustments in African-American Patients, Patients with Hepatic Impairment, Drug Interactions

African-American patients, compared to Caucasian patients, may need to be titrated to higher ENVARSUS XR dosages toattain comparable trough concentrations [see Use in Specific Populations (8.8), Clinical Pharmacology (12.3)].

Due to reduced clearance and prolonged half-life seen in patients with severe hepatic impairment (Child-Pugh ≥10) thesepatients may require a lower starting dosage of ENVARSUS XR [see Clinical Pharmacology (12.3)].

Dose adjustments of ENVARSUS XR may be necessary when administered concomitantly with CYP3A inducers orCYP3A inhibitors or cannabidiol [see Warnings and Precautions (5.9, 5.13), Drug Interactions (7.2, 7.3)].

Therapeutic Drug Monitoring

Measure tacrolimus whole blood trough concentrations at least two times on separate days during the first week after initiation of dosing and after any change in dosage, after a change in co-administration of CYP3A inducers and/or inhibitors or cannabidiol [see Drug Interactions (7)], or after a change in renal or hepatic function [see Use in Specific Populations (8.6, 8.7)]. When interpreting measured concentrations, consider that the time to achieve tacrolimus steady state is approximately 7 days after initiating or changing the ENVARSUS XR dose.

Monitor tacrolimus whole blood trough concentrations using a validated assay [e.g., immunoassays or high-performanceliquid chromatography with tandem mass spectrometric detection (HPLC/MS/MS)]. The immunosuppressive activity oftacrolimus is mainly due to the parent drug rather than to its metabolites. Immunoassays may react with metabolites aswell as the parent drug. Therefore, whole blood tacrolimus trough concentrations obtained with immunoassays may benumerically higher than concentrations obtained with an assay using HPLC/MS/MS. Comparison of the whole bloodtacrolimus trough concentrations of patients to those described in the prescribing information and other publishedliterature must be made with knowledge of the assay method(s) employed.

Pregnancy

Pregnancy Exposure Registry

There is a pregnancy registry that monitors pregnancy outcomes in women exposed to ENVARSUS XR during pregnancy. The Transplantation Pregnancy Registry International (TPRI) is a voluntary pregnancy exposure registry that monitors outcomes of pregnancy in female transplant recipients and those fathered by male transplant recipients exposed to immunosuppressants including tacrolimus. Healthcare providers are encouraged to advise their patients to register by contacting the Transplantation Pregnancy Registry International at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.

Risk Summary

Tacrolimus can cause fetal harm when administered to a pregnant woman. Data from postmarketing surveillance andTPRI suggest that infants exposed to tacrolimus in utero are at a risk of prematurity, birth defects/congenital anomalies,low birth weight, and fetal distress [see Human Data]. Advise pregnant women of the potential risk to the fetus.

Administration of oral tacrolimus to pregnant rabbits and rats throughout the period of organogenesis was associated withmaternal toxicity/lethality, and an increased incidence of abortion, malformation and embryofetal death at clinicallyrelevant doses (0.7 to 3.7 times the recommended clinical dose [0.14 mg/kg/day], on a mg/m² basis). Administration oforal tacrolimus to pregnant rats after organogenesis and throughout lactation produced maternal toxicity, effects onparturition, reduced pup viability and reduced pup weight at clinically relevant doses (1.2 to 3.7 times the recommendedclinical dose, on a mg/m² basis). Administration of oral tacrolimus to rats prior to mating, and throughout gestation andlactation produced maternal toxicity/lethality, marked effects on parturition, embryofetal loss, malformations, and reducedpup viability at clinically relevant doses (1.2 to 3.7 times the recommended clinical dose, on a mg/m² basis). Interventricular septal defects, hydronephrosis, craniofacial malformations and skeletal effects were observed in offspringthat died [see Animal Data].

The background risk of major birth defects and miscarriage in the indicated population is unknown. In the U.S. generalpopulation, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2to 4 % and 15 to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk

Risks during pregnancy are increased in organ transplant recipients.

The risk of premature delivery following transplantation is increased. Pre-existing hypertension and diabetes conferadditional risk to the pregnancy of an organ transplant recipient. Pre-gestational and gestational diabetes are associatedwith birth defects/congenital anomalies, hypertension, low birth weight and fetal death.

Cholestasis of pregnancy (COP) was reported in 7% of liver or liver-kidney (LK) transplant recipients, compared withapproximately 1% of pregnancies in the general population. However, COP symptoms resolved postpartum and no long-termeffects on the offspring were reported.

Maternal Adverse Reactions

ENVARSUS XR may increase hyperglycemia in pregnant women with diabetes (including gestational diabetes). Monitormaternal blood glucose levels regularly [see Warnings and Precautions (5.4)].

ENVARSUS XR may exacerbate hypertension in pregnant women and increase pre-eclampsia. Monitor and control bloodpressure [see Warnings and Precautions (5.7, 5.8)].

Fetal/Neonatal Adverse Reactions

Renal dysfunction, transient neonatal hyperkalemia and low birth weight have been reported at the time of delivery ininfants of mothers taking ENVARSUS XR.

Labor or Delivery

There is an increased risk for premature delivery (<37 weeks) following transplantation and maternal exposure toENVARSUS XR.

Data

Human Data

There are no adequate and well controlled studies on the effects of tacrolimus in human pregnancy.

Safety data from the TPRI and postmarketing surveillance suggest infants exposed to tacrolimus in utero have anincreased risk for miscarriage, pre-term delivery (<37 weeks), low birth weight (<2500 g), birth defects/congenitalanomalies and fetal distress.

TPRI reported 450 and 241 total pregnancies in kidney and liver transplant recipients exposed to tacrolimus,respectively. The TPRI pregnancy outcomes are summarized in Table 8. In the table below, the number of recipientsexposed to tacrolimus concomitantly with mycophenolic acid (MPA) products during the preconception and first trimesterperiods is high (27% and 29% for renal and liver transplant recipients, respectively). Because MPA products may alsocause birth defects, the birth defect rate may be confounded and this should be taken into consideration when reviewingthe data, particularly for birth defects. Birth defects observed include cardiac malformations, craniofacial malformations,renal/urogenital disorders, skeletal abnormalities, neurological abnormalities and multiple malformations.

*Includes multiple births and terminations.
†Birth defect rate confounded by concomitant MPA products exposure in over half of offspring with birth defects.

Additional information reported by TPRI in pregnant transplant patients receiving tacrolimus included diabetes duringpregnancy in 9% of kidney recipients and 13% of liver recipients and hypertension during pregnancy in 53% of kidneyrecipients and 16.2% of liver recipients.

Animal Data

Administration of oral tacrolimus to pregnant rabbits throughout organogenesis produced maternal toxicity and abortion at0.32 mg/kg (0.7 times the recommended clinical dose based on body surface area). At 1 mg/kg (2.3 times therecommended clinical dose) embryofetal lethality and fetal malformations (ventricular hypoplasia, interventricular septaldefect, bulbous aortic arch, stenosis of ductus arteriosus, omphalocele, gallbladder agenesis, skeletal anomalies) wereobserved. Administration of 3.2 mg/kg oral tacrolimus (3.7 times the recommended clinical dose) to pregnant ratsthroughout organogenesis produced maternal toxicity/lethality, embryofetal lethality and decreased fetal body weight inthe offspring of C-sectioned dams; and decreased pup viability and interventricular septal defect in offspring of dams thatdelivered.

In a peri/postnatal development study, oral administration of tacrolimus to pregnant rats during late gestation (afterorganogenesis) and throughout lactation produced maternal toxicity, effects of parturition, and reduced pup viability at3.2 mg/kg (3.7 times the recommended clinical dose); among these pups that died early, an increased incidence of kidneyhydronephrosis was observed. Reduced pup weight was observed at 1mg/kg (1.2 times the recommended clinical dose).

Administration of oral tacrolimus to rats prior to mating, and throughout gestation and lactation produced maternaltoxicity/lethality, embryofetal loss and reduced pup viability at 3.2 mg/kg (3.7 times the recommended clinical dose).Interventricular septal defects, hydronephrosis, craniofacial malformations and skeletal effects were observed in offspringthat died. Effects on parturition (incomplete delivery of nonviable pups) were observed at 1 mg/kg (1.2 times therecommended clinical dose) [see Nonclinical Toxicology (13.1)].

Lactation

Risk Summary

Controlled lactation studies have not been conducted in humans; however tacrolimus has been reported to be present inhuman milk. The effects of tacrolimus on the breastfed infant, or on milk production have not been assessed. Tacrolimus isexcreted in rat milk and in peri-/postnatal rat studies, exposure to tacrolimus during the postnatal period was associated withdevelopmental toxicity in the offspring at clinically relevant doses [see Pregnancy (8.1), Nonclinical Toxicology (13.1)].

The development and health benefits of breastfeeding should be considered along with the mother’s clinical need forENVARSUS XR and any potential adverse effects on the breastfed child from ENVARSUS XR or from the underlyingmaternal condition.

Females and Males of Reproductive Potential

Contraception

ENVARSUS XR can cause fetal harm when administered to pregnant women. Advise female and male patients ofreproductive potential to speak with their healthcare provider on family planning options including appropriatecontraception prior to starting treatment with ENVARSUS XR [see Use in Specific Populations (8.1), NonclinicalToxicology (13.1)].

Infertility

Based on findings in animals, male and female fertility may be compromised by treatment with ENVARSUS XR [see Nonclinical Toxicology (13.1)].

Pediatric Use

The safety and effectiveness of ENVARSUS XR in pediatric patients have not been established.

Geriatric Use

Clinical studies of ENVARSUS XR did not include sufficient numbers of patients aged 65 and over to determine whetherthey respond differently from younger patients. In Studies 1, 2 and 3, there were 37 patients 65 years of age and older,and no patients were over 75 years [see Clinical Studies (14)]. Other reported clinical experience has not identifieddifferences in responses between the elderly and younger patients. In general, dose selection for an elderly patient shouldbe cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,renal, or cardiac function, and of concomitant disease or other drug therapy.

Renal Impairment

The pharmacokinetics of tacrolimus in patients with renal impairment was similar to that in healthy subjects with normal renal function. However, due to its potential for nephrotoxicity, monitoring of renal function in patients with renal impairment is recommended; tacrolimus dosage should be reduced if indicated [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)].

Hepatic Impairment

The mean clearance of tacrolimus was substantially lower in patients with severe hepatic impairment (mean Child-Pugh score: >10) compared to healthy subjects with normal hepatic function [see Clinical Pharmacology (12.3)]. With greater tacrolimus whole blood trough concentrations in patients with severe hepatic impairment, there is a greater risk of adverse reactions and dosage reduction is recommended [see Dosage and Administration (2.4)]. For patients with moderate hepatic impairment, monitor tacrolimus whole blood trough concentrations. For patients with mild hepatic impairment, no dosage adjustments are needed.

Race

African-American patients may need to be titrated to higher ENVARSUS XR dosages to attain comparable troughconcentrations compared to Caucasian patients. The pharmacokinetics of ENVARSUS XR were evaluated in a study of46 stable African-American kidney transplant recipients converted from tacrolimus immediate-release to ENVARSUSXR and indicated that an 80% conversion factor is appropriate for African-American patients [see Dosage andAdministration (2.4), Clinical Pharmacology (12.3)].

African-American and Hispanic kidney transplant patients are at an increased risk for new onset diabetes after transplant.Monitor blood glucose concentrations and treat appropriately [see Warnings and Precautions (5.4)].

Lymphoma and Other Malignancies

Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies,particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than tothe use of any specific agent. Examine patients for skin changes and advise to avoid or limit exposure to sunlight and UVlight by wearing protective clothing and using a sunscreen with a high protection factor.

Post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV), has been reported inimmunosuppressed organ transplant patients. The risk of PTLD appears greatest in those individuals who are EBVseronegative. Monitor EBV serology during treatment.

Serious Infections

Immunosuppressants, including ENVARSUS XR, increase the risk of developing bacterial, viral, fungal, and protozoalinfections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. Seriousviral infections reported include:

• Polyomavirus-associated nephropathy (especially due to BK virus infection),
• JC virus-associated progressive multifocal leukoencephalopathy (PML), and
• Cytomegalovirus (CMV) infections: CMV seronegative transplant patients who receive an organ from a CMVseropositive donor are at highest risk of CMV viremia and CMV disease.

Monitor for the development of infection and adjust the immunosuppressive regimen to balance the risk of rejection with the risk of infection [see Adverse Reactions (6.1)].

Not Interchangeable with Other Tacrolimus Products-Medication Errors

Medication errors, including substitution and dispensing errors, between tacrolimus capsules and tacrolimus extended-releasecapsules were reported outside the U.S. This led to serious adverse reactions, including graft rejection, or otheradverse reactions due to under- or over-exposure to tacrolimus. ENVARSUS XR is not interchangeable or substitutablewith tacrolimus extended-release capsules, tacrolimus capsules or tacrolimus for oral suspension. Instruct patients andcaregivers to recognize the appearance of ENVARSUS XR tablet [see Dosage Forms and Strengths (3)] and to confirm with their healthcare provider if a different product is dispensed or if dosing instructions have changed.

New Onset Diabetes after Transplant

ENVARSUS XR caused new onset diabetes after transplant (NODAT) in kidney transplant patients, which may be reversible in some patients. African-American and Hispanic kidney transplant patients are at an increased risk. Monitor blood glucose concentrations and treat appropriately [see Adverse Reactions (6.1) and Use in Specific Populations (8.8)].

Nephrotoxicity due to ENVARSUS XR and Drug Interactions

ENVARSUS XR, like other calcineurin-inhibitors, can cause acute or chronic nephrotoxicity in transplant patients due to its vasoconstrictive effect on renal vasculature, toxic tubulopathy and tubular-interstitial effects. Acute renal impairment associated with tacrolimus toxicity can result in high serum creatinine, hyperkalemia, decreased secretion of urea and hyperuricemia, and is usually reversible. In patients with elevated serum creatinine and tacrolimus whole blood trough concentrations greater than the recommended range, consider dosage reduction or temporary interruption of tacrolimus administration.

The risk for nephrotoxicity may increase when ENVARSUS XR is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). When tacrolimus is used concurrently with CYP3A inhibitors or other known nephrotoxic drugs, monitor renal function and tacrolimus blood concentrations, and adjust dose of both tacrolimus and/or concomitant medications during concurrent use [see Adverse Reactions (6.1, 6.2) and Drug Interactions (7.2)].

Neurotoxicity

ENVARSUS XR may cause a spectrum of neurotoxicities. The most severe neurotoxicities include posterior reversibleencephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremors, paresthesias, headache, mentalstatus changes, and changes in motor and sensory functions [see Adverse Reactions ]. Monitor serum potassium levelsperiodically during treatment.

Hypertension

Hypertension is a common adverse reaction of ENVARSUS XR therapy and may require antihypertensive therapy [see Adverse Reactions (6.1)]. Some antihypertensive drugs can increase the risk for hyperkalemia [see Warnings and Precautions (5.7)]. Calcium-channel blocking agents may increase tacrolimus blood concentrations and require dosage reduction of ENVARSUS XR [see Drug Interactions (7.2)].

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors

The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. In contrast, the concomitant use of strong CYP3A inhibitors may decrease the metabolism of tacrolimus, leading to higher whole blood trough concentrations and greater risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.10)]. Therefore, adjustENVARSUS XR dose and monitor tacrolimus whole blood trough concentrations when co-administering ENVARSUS XRwith strong CYP3A inhibitors (e.g., including but not limited to telaprevir, boceprevir, ritonavir, ketoconazole,itraconazole, voriconazole, clarithromycin) or strong CYP3A inducers (e.g., including but not limited to rifampin,rifabutin) [see Dosage and Administration (2.4, 2.5), Drug Interactions (7.2)]. A rapid, sharp rise in tacrolimus levels has been reported after co-administration with strong CYP3A4 inhibitors despite an initial reduction of tacrolimus dose. Early and frequent monitoring of tacrolimus whole blood trough levels is recommended [see Drug Interactions (7.2)].

QT Prolongation

ENVARSUS XR may prolong the QT/QTc interval and cause Torsades de pointes. Avoid ENVARSUS XR in patientswith congenital long QT syndrome. Consider obtaining electrocardiograms and monitoring electrolytes (magnesium,potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those takingcertain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances(e.g., hypokalemia, hypocalcemia, or hypomagnesemia).

When co-administering ENVARSUS XR with other substrates and/or inhibitors of CYP3A, especially those that also have the potential to prolong the QT interval, a reduction in ENVARSUS XR dosage, monitoring of tacrolimus whole blood concentrations, and monitoring for QT prolongation is recommended [see Dosage and Administration (2.5), Drug Interactions (7.2)].

Immunizations

Whenever possible, administer the complete complement of vaccines before transplantation and treatment withENVARSUS XR.

Avoid the use of live attenuated vaccines during treatment with ENVARSUS XR (e.g., intranasal influenza, measles,mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines).

Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic duringtreatment with ENVARSUS XR.

Pure Red Cell Aplasia

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. All of these patients reportedrisk factors for PRCA such as parvovirus B19 infection, underlying disease, or concomitant medications associated withPRCA. A mechanism for tacrolimus-induced PRCA has not been elucidated. If PRCA is diagnosed, considerdiscontinuation of ENVARSUS XR.

5.13 Cannabidiol Drug Interactions

When cannabidiol and ENVARSUS XR are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. A dose reduction of ENVARSUS XR should be considered as needed when ENVARSUS XR is co-administered with cannabidiol [see Dosage and Administration (2.4, 2.5), Drug Interactions (7.3)].

Thrombotic Microangiopathy (TMA) Including Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura

Cases of thrombotic microangiopathy (TMA), including hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), have been reported in patients treated with ENVARSUS XR. TMA may have a multifactorial etiology. Risk factors for TMA that can occur in transplant patients include, for example, severe infections, graft-versus-host disease (GVHD), Human Leukocyte Antigen (HLA) mismatch, the use of calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors. These risk factors may, either alone or combined, contribute to the risk of TMA.

In patients with signs and symptoms of TMA, consider ENVARSUS XR as a risk factor. Concurrent use of ENVARSUS XR and mTOR inhibitors may contribute to the risk of TMA.

Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinicalstudies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the ratesobserved in practice. In addition, the clinical studies were not designed to establish comparative differences across studyarms with regards to the adverse reactions discussed below.

Study 1- Phase 3 Clinical Study in De Novo Kidney Transplant Recipients

Study 1 (NCT 01187953), was a Phase 3 randomized study in de novo kidney transplant patients that were treated withENVARSUS XR (N=268) or tacrolimus [immediate-release] capsules (N=275) and concomitant immunosuppressants in adouble-blind, randomized, multinational study [see Clinical Studies (14.1)]. The proportion of patients who discontinuedtreatment due to adverse reactions was 8.6% and 9.8% in the ENVARSUS XR and tacrolimus capsules treatment groups,respectively, through 12 months of treatment. The most common adverse reactions leading to discontinuation of studydrug in the ENVARSUS XR treatment group were esophagitis, polyomavirus-associated nephropathy, graft dysfunction,complications of transplanted kidney, and diabetes mellitus, each resulting in 0.7% discontinuations among ENVARSUSXR treatment patients. In Study 1, de novo kidney transplant patients who received a starting dose of 0.17 mg/kg/day,which is higher than the recommended ENVARSUS XR starting dose of 0.14 mg/kg/day, exceeded the recommendedtarget tacrolimus trough concentrations as high as 57 ng/mL during the first 1 to 2 weeks post-transplant [see Dosage and Administration (2.2)].

Infections

The overall incidence of infections, serious infections, and infections with identified etiology reported in de novo kidneytransplant recipients treated with ENVARSUS XR or tacrolimus [immediate-release] capsules in Study 1 are shown in Table 2.

New Onset Diabetes After Transplantation

New onset diabetes after transplantation (NODAT) was defined by the composite occurrence of fasting plasma glucosevalues ≥126 mg/dL, 2-hour post-prandial plasma glucose of at least 200 mg/dL (in oral glucose tolerance test) on two ormore consecutive occasions post-baseline, insulin requirement for ≥31 days, an oral hypoglycemic agent use ≥31 days, orHbA1c ≥6.5% (at least 3 months after randomization) among kidney transplant patients with no medical history ofdiabetes. The incidence of NODAT for Study 1 through one year post-transplant is summarized in Table 3 below [see Warnings and Precautions (5.4)].

Common Adverse Reactions

The incidence of adverse reactions that occurred in ≥10% of ENVARSUS XR-treated patients compared to tacrolimus[immediate-release] capsules through one year of treatment in Study 1 is shown by treatment group in Table 4 .

Study 2- Phase 2 Clinical Study in De Novo Kidney Transplant Recipients

Study 2 (NCT00765661) was an open-label Phase 2 study conducted in de novo kidney transplant patients randomized toonce daily ENVARSUS XR (N=32) or twice daily tacrolimus [immediate-release] capsules (N=31). The study wasconducted in the US and patients received an organ from a deceased or living donor. Pharmacokinetics were evaluatedduring the first 2 weeks with an additional 50-week treatment and follow-up to evaluate safety and efficacy [see ClinicalStudies (14.1)].

The starting dosage was 0.14 mg/kg/day (given once daily) for ENVARSUS XR and 0.2 mg/kg/day (given twice daily)for tacrolimus [immediate-release] capsules. On Day 2 predose, the proportion of patients in the ENVARSUS XR groupwith tacrolimus trough concentration that were within, above, and below 6 to 11 ng/mL was 53%, 11%, and 37%,respectively. The starting dose of 0.14 mg/kg/day in Study 2 formed the basis of dosing recommendations in de novokidney transplant patients.

There were no deaths or graft failures in Study 2. Two patients in each arm discontinued due to adverse events. The mostcommon adverse reactions included infections and cardiovascular events, and were generally similar to those reported inStudy 1.

Study 3- Phase 3 Clinical Studies in Stable Kidney Transplant Recipients Converted from Tacrolimus Capsules

In Study 3 (NCT00817206) stable kidney transplant patients were treated with ENVARSUS XR (N=162) or tacrolimus[immediate-release] capsules (N=162) and concomitant immunosuppressants in an open-label, randomized, multinationalstudy [see Clinical Studies (14.2)]. The proportion of patients who discontinued treatment due to adverse reactions was7.4% and 1.2% in the ENVARSUS XR and tacrolimus capsules treatment groups, respectively, through 12 months oftreatment. The most common adverse reactions leading to discontinuation of study drug in the ENVARSUS XR treatmentgroup was cardiac arrest (2 events).

Infections

The overall incidence of infections, serious infections, and infections with identified etiology reported in stable kidneytransplant recipients treated with ENVARSUS XR or tacrolimus capsules are shown in Table 5.

New Onset Diabetes After Transplantation

New onset diabetes after transplantation (NODAT) was defined by the composite occurrence of fasting plasma glucosevalues ≥126 mg/dL, 2-hour postprandial plasma glucose of at least 200 mg/dL (in oral glucose tolerance test) on 2 or moreconsecutive occasions post-baseline, insulin requirement for ≥31 days, an oral hypoglycemic agent use ≥31 days, orHbA1c ≥6.5% (at least 3 months after randomization) among kidney transplant patients with no medical history ofdiabetes. The incidence of NODAT for the stable kidney transplant study through one year post-transplant is summarizedin Table 6 below [see Warnings and Precautions (5.4)].

Common Adverse Reactions

In Study 3, the most common (≥10%) adverse reactions observed with Envarsus XR were diarrhea (14%), and bloodcreatinine increased (12%).

Postmarketing Experience

The following adverse reactions have been reported from marketing experience with tacrolimus in the U.S. and outsidethe U.S. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible toreliably estimate their frequency or establish a causal relationship to drug exposure. The following reactions have beenincluded due to either their seriousness, frequency of reporting or strength of causal connection to ENVARSUS XR:

• Blood and Lymphatic System Disorders: Agranulocytosis, decreased blood fibrinogen, disseminated intravascular coagulation, hemolytic anemia, hemolytic uremic syndrome, leukopenia, febrile neutropenia, pancytopenia, prolonged activated partial thromboplastin time, pure red cell aplasia [see Warnings and Precautions (5.12)], thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombotic microangiopathy
• Cardiac Disorders: Atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac arrest, electrocardiogram T wave abnormal, flushing, myocardial hypertrophy, myocardial infarction, myocardial ischaemia, pericardial effusion, QT prolongation, supraventricular extrasystoles, supraventricular tachycardia, Torsades de pointes, deep limb venous thrombosis, ventricular fibrillation
• Ear Disorders: Hearing loss including deafness
• Eye Disorders: Blindness, optic neuropathy, photophobia, optic atrophy
• Gastrointestinal Disorders: Abdominal pain, colitis, dysphagia, gastrointestinal perforation, impaired gastric emptying, intestinal obstruction, mouth ulceration, peritonitis, stomach ulcer
• Hepatobiliary Disorders: Bile duct stenosis, cholangitis, cirrhosis, fatty liver, hepatic cytolysis, hepatic failure, hepatic necrosis, hepatic steatosis, jaundice, hemorrhagic pancreatitis, necrotizing pancreatitis, venoocclusive liver disease, hepatitis (acute and chronic)
• Hypersensitivity Reactions: Hypersensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
• Immune System Disorders: Graft versus host disease (acute and chronic)
• Metabolism and Nutrition Disorders: Glycosuria, increased amylase, pancreatitis
• Musculoskeletal and Connective Tissue Disorders: Myalgia, polyarthritis, rhabdomyolysis
• Neoplasms: Lymphoma including EBV-associated lymphoproliferative disorder, PTLD [see Warnings and Precautions (5.1)]; leukemia
• Nervous System Disorders: Carpal tunnel syndrome, cerebral infarction, coma, dysarthria, flaccid paralysis, hemiparesis, mental disorder, mutism, nerve compression, posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.6)], progressive multifocal leukoencephalopathy (PML) sometimes fatal [see Warnings and Precautions (5.2)], quadriplegia, speech disorder, status epilepticus, syncope
• Renal and Urinary Disorder: Acute renal failure, hemorrhagic cystitis, hemolytic uremic syndrome, micturition disorder
• Respiratory, Thoracic and Mediastinal Disorders: Acute respiratory distress syndrome, interstitial lung disease, lunginfiltration, pulmonary embolism, pulmonary hypertension, respiratory distress, respiratory failure
• Skin and Subcutaneous Tissue Disorders: Hyperpigmentation, photosensitivity, pruritus, rash

Mycophenolic Acid

When ENVARSUS XR is prescribed with a given dose of mycophenolic acid (MPA) product, exposure to MPA is higherwith ENVARSUS XR co-administration than with cyclosporine co-administration with MPA, because cyclosporineinterrupts the enterohepatic recirculation of MPA while tacrolimus does not. Monitor for MPA associated adversereactions and reduce the dose of concomitantly administered MPA products as needed.

Effects of Other Drugs/Substances on ENVARSUS XR

Direct Acting Antiviral (DAA) Therapy

The pharmacokinetics of tacrolimus may be impacted by changes in liver function during DAA therapy, related to clearance of HCV virus. Close monitoring and potential dose adjustment of tacrolimus is warranted to ensure continued efficacy.

Cannabidiol

The blood levels of tacrolimus may increase upon concomitant use with cannabidiol. When cannabidiol and ENVARSUS XR are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. A dose reduction of ENVARSUS XR should be considered as needed when ENVARSUS XR is co-administered with cannabidiol [see Dosage and Administration (2.5) and Warnings and Precautions (5.13)].

Mechanism of Action

Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, andcalcineurin (an ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurininhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor ofactivated T-cells (NF-AT) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB).

Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3,IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor-alpha, and granulocyte macrophage colony stimulating factor. Tacrolimus also inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis andproduction of transforming growth factor-beta that can lead to immunosuppressive activity. The net result is the inhibitionof T-lymphocyte activation and proliferation as well as T-helper-cell-dependent B-cell response (i.e.,immunosuppression).

Pharmacokinetics

Table 9 summarizes the pharmacokinetic (PK) parameters of tacrolimus following oral administration of once-daily ENVARSUS XR in healthy subjects and in kidney transplant patients, under fasted conditions. Whole blood tacrolimus concentrations in the pharmacokinetic studies were measured using validated HPLC/MS/MS assays.

In de novo adult kidney transplant patients, the administration of ENVARSUS XR once daily at a starting dose of0.14 mg/kg/day results in a tacrolimus systemic exposure (AUC24) on Day 1 post-transplant that is up to 10% lower thanthat of tacrolimus immediate-release capsules twice daily administered at a starting dose of 0.1 mg/kg/day, while similartacrolimus trough concentrations (C24) are achieved. As steady state is achieved (typically within 7 days of stableENVARSUS XR dosing), the AUC24 of ENVARSUS XR is approximately 15% higher than that of tacrolimus immediate-releasecapsules, at comparable trough concentrations (C24).

In adult kidney transplant patients ≥ 6 months post-transplant switched to ENVARSUS XR at 67% to 80% of the dailydose of tacrolimus immediate-release capsules, the steady state tacrolimus exposures (AUC24) and tacrolimus troughconcentrations (C24) were comparable to the AUC24 and C24 measured prior to the switch. However, the mean Cmaxestimate was 30% lower and the median Tmax was more prolonged (6 hours versus 2 hours) following administration ofEnvarsus XR as compared to that of tacrolimus immediate-release capsules.

Absorption

Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. In de novokidney transplant patients, the median time to achieve maximum blood concentrations (Cmax) of ENVARSUS XR wasapproximately 6 to 10 hours (Tmax) on day 1 post-transplant; the median Tmax at steady state was 4 to 6 hours. In healthysubjects, the oral bioavailability of ENVARSUS XR was approximately 50% higher as compared with both tacrolimusimmediate-release and extended-release capsule formulations at steady state. In healthy subjects who received singleENVARSUS XR doses ranging from 5 mg to 10 mg, the mean AUC and C24 of tacrolimus increased linearly and theelimination half-life did not change with increasing doses.

Food Effects

The presence of a meal affects the absorption of tacrolimus; the rate and extent of absorption is greatest under fastedconditions. In 26 healthy subjects, administration of ENVARSUS XR following a high-fat breakfast reduced the systemicexposure (AUC) to tacrolimus by approximately 55% and the peak plasma concentration of tacrolimus (Cmax) by 22%,with no effect on the time to reach maximum plasma concentration (Tmax), compared to when ENVARSUS XR wasadministered under fasted conditions. ENVARSUS XR tablets should be taken preferably on an empty stomach at least 1hour before a meal or at least 2 hours after a meal.

Chronopharmacokinetic Effect

In 26 healthy subjects, administration of ENVARSUS XR tablets in the evening resulted in a 15% lower AUC0-inf and a20% lower C24, as compared to morning dosing.

Distribution

The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50ng/mL. Tacrolimus is bound mainly to albumin and alpha-1-acid glycoprotein, and has a high level of association witherythrocytes. The distribution of tacrolimus between whole blood and plasma depends on several factors, such ashematocrit, temperature at the time of plasma separation, drug concentration, and plasma protein concentration. In a U.S.trial in which tacrolimus was administered as immediate-release formulation, the ratio of whole blood concentration toplasma concentration averaged 35 (range 12 to 67).

Metabolism

The desired pharmacological activity of tacrolimus is primarily due to the parent drug. Tacrolimus is extensivelymetabolized by the mixed-function oxidase system, primarily the cytochrome P-450 system 3A (CYP3A4 and CYP3A5). A metabolicpathway leading to the formation of 8 possible metabolites has been proposed. Demethylation and hydroxylation wereidentified as the primary mechanisms of biotransformation in vitro. The major metabolite identified in incubations withhuman liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported tohave the same activity as tacrolimus.

Excretion

In a mass balance study of orally administered radiolabeled tacrolimus to 6 healthy subjects, the mean recovery of theradiolabel was 94.9 ± 30.7%. Fecal elimination accounted for 92.6 ± 30.7% and urinary elimination accounted for 2.3 ±1.1% of the total radiolabel administered. The elimination half-life based on radioactivity was 31.9 ± 10.5 hours, whereasit was 48.4 ± 12.3 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.226 ± 0.116 L/hr/kgand the mean clearance of tacrolimus was 0.172 ± 0.088 L/hr/kg.

The elimination half-life of tacrolimus after oral administration of 2 mg ENVARSUS XR once-daily for 10 days was 31.0± 8.1 hours (mean ± SD) in 25 healthy subjects.

Specific Populations

Patients With Renal Impairment

Tacrolimus pharmacokinetics following a single administration of tacrolimus (administered as a continuous IV infusion)were determined in 12 patients (7 not on dialysis and 5 on dialysis, serum creatinine of 3.9±1.6 and 12.0±2.4 mg/dL,respectively) prior to their kidney transplant. The mean clearance of tacrolimus in patients with renal dysfunction givenIV tacrolimus was similar to that in healthy subjects given tacrolimus IV and in healthy subjects given oral tacrolimusimmediate-release [see Use In Specific Populations (8.6)].

Patients With Hepatic Impairment

Tacrolimus pharmacokinetics have been determined in 6 patients with mild hepatic impairment (mean Pugh score: 6.2) following single oral administration of tacrolimus immediate-release. The mean clearance of tacrolimus in patients with mild hepatic impairment was not substantially different from that in healthy subjects. Tacrolimus pharmacokinetics were studied in 6 patients with severe hepatic impairment (mean Pugh score: >10). The mean clearance was substantially lower in patients with severe hepatic impairment [see Dosage and Administration (2.3) and Use in Specific Populations (8.7)].

Racial or Ethnic Groups

The pharmacokinetics of ENVARSUS XR were evaluated in a study of 46 stable African American kidney transplant recipients converted from tacrolimus immediate-release to ENVARSUS XR. Approximately 80% of the African American patients were carriers of the active, wild type CYP3A5*1 allele. Regardless of genotype status, the PK results demonstrated similar exposure, lower Cmax, prolonged Tmax, and increased bioavailability compared to tacrolimus immediate-release [see Dosage and Administration (2.3) and Use in Specific Populations (8.8)].

Male and Female Patients

A formal trial to evaluate the effect of gender on tacrolimus pharmacokinetics has not been conducted. In a sub-group analysis from the two combined Phase 3 studies in kidney transplant recipients (Study 1 and Study 3) performed with ENVARSUS XR over one year of treatment, no gender-dependent differences in tacrolimus systemic exposures were observed.

Drug Interaction Studies

Because tacrolimus is metabolized mainly by CYP3A enzymes, drugs or substances known to inhibit these enzymes and/or are known CYP3A substrates may increase tacrolimus whole blood concentrations. Drugs known to induce CYP3A enzymes may decrease tacrolimus whole blood concentrations [see Warnings and Precautions (5.9) and Drug Interactions (7.2)].

Voriconazole: Co-administration of ENVARSUS XR with voriconazole following 400 mg BID of voriconazole resulted in a tacrolimus mean AUCinf increase by 2.62 fold and Cmax by 2.03 fold.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies were conducted in male and female rats and mice. In the 80-week mouse oral study and in the 104-week rat oral study, no relationship of tumor incidence to tacrolimus dosage was found. The highest dose used in the mouse was 3mg/kg/day (0.84 times the AUC at the recommended clinical dose of 0.14 mg/kg/day ) and in the rat was 5 mg/kg/day (0.24 times the AUC at the recommended clinical dose of 0.14 mg/kg/day) [see Boxed Warning and Warnings and Precautions (5.1)].

A 104-week dermal carcinogenicity study was performed in mice with tacrolimus ointment (0.03%-3%), equivalent totacrolimus doses of 1.1-118 mg/kg/day or 3.3-354 mg/m2/day. In the study, the incidence of skin tumors was minimal andthe topical application of tacrolimus was not associated with skin tumor formation under ambient room lighting. However,a statistically significant elevation in the incidence of pleomorphic lymphoma in high-dose male (25/50) and femaleanimals (27/50) and in the incidence of undifferentiated lymphoma in high-dose female animals (13/50) was noted in themouse dermal carcinogenicity study. Lymphomas were noted in the mouse dermal carcinogenicity study at a daily dose of3.5 mg/kg (0.1% tacrolimus ointment; 2.5-fold the human exposure in stable adult renal transplant patients converted from tacrolimus immediate-release product to ENVARSUS XR). No drug-related tumors were noted in the mouse dermalcarcinogenicity study at a daily dose of 1.1 mg/kg (0.03% tacrolimus ointment). The relevance of topical administration oftacrolimus in the setting of systemic tacrolimus use is unknown.

The implications of these carcinogenicity studies are limited; doses of tacrolimus were administered that likely inducedimmunosuppression in these animals, impairing their immune system’s ability to inhibit unrelated carcinogenesis.

Mutagenesis

No evidence of genotoxicity was seen in bacterial (Salmonella and E. coli) or mammalian (Chinese hamster lung-derived cells) in vitro assays of mutagenicity, the in vitro CHO/HGPRT assay of mutagenicity, or in vivo clastogenicity assays performed in mice; tacrolimus did not cause unscheduled DNA synthesis in rodent hepatocytes.

Impairment of Fertility

Tacrolimus subcutaneously administered to male rats at paternally toxic doses of 2 mg/kg/day (2.3 times therecommended clinical dose based on body surface area) or 3 mg/kg/day (3.4 times the recommended clinical dose basedon body surface area) resulted in a dose-related decrease in sperm count. Tacrolimus administered orally at 1mg/kg (1.2times the recommended clinical dose based on body surface area) to male and female rats, prior to and during mating, aswell as to dams during gestation and lactation, was associated with embryolethality and adverse effects on femalereproduction. Effects on female reproductive function (parturition) and embryolethal effects were indicated by a higherrate of pre- and post-implantation loss and increased numbers of undelivered and nonviable pups. When administered at3.2 mg/kg (3.7 times the recommended clinical dose based on body surface area), tacrolimus was associated with maternaland paternal toxicity as well as reproductive toxicity including marked adverse effects on estrus cycles, parturition, pupviability, and pup malformations.

Clinical Studies in De Novo Kidney Transplant Recipients

Study 1

Study 1 (NCT 01187953) was a Phase 3, 12-month, randomized, double-blind, multinational study comparing once daily ENVARSUS XR (N=268) to twice daily tacrolimus [immediate-release] capsules (N=275) in patients who received a de novo kidney transplant. Patients received the first dose of the study drug anytime within 48 hours of graft reperfusion. All patients received only IL-2 receptor antagonist induction therapy and concomitant treatment with mycophenolate mofetil (MMF) and corticosteroids. Approximately 97% of all patients received antibody induction therapy with basiliximab and 91% of all patients received corticosteroids and MMF.

The mean age of the study population was 46 years; 65% were male; 77% were Caucasian, 5% were African-American, 4% were Asian and 14% were categorized as other races. Living donors provided 49% of the organs and 51% of patients received a kidney transplant from a deceased donor. Patients with clinically relevant ECG abnormalities (including QTc prolongation and reversible ischemia) and clinically symptomatic congestive heart failure or patients with documented left ventricular ejection fraction of less than 45% were excluded. Patients with a panel reactive antibody (PRA) >30%, who received a kidney from a non-heart-beating donor or with cold ischemia time >30 hours were also excluded. Premature discontinuation from treatment at the end of one year occurred in 22% of ENVARSUS XR patients and 19% of tacrolimus [immediate-release] capsules patients.

Tacrolimus Therapy

In Study 1, de novo kidney transplant patients were dosed initially at a starting dosage of 0.17 mg/kg given once daily for ENVARSUS XR (approximately 1.2-fold higher than the recommended starting dosage) and 0.1 mg/kg/day (given twice daily) for tacrolimus [immediate-release] capsule, with doses then modified to maintain tacrolimus trough concentrations between 6-11 ng/mL for the first 30 days and then between 4-11 ng/L for the remainder of the study. In the first week of dosing, the tacrolimus doses administered were, on average, ~40% higher in the ENVARSUS XR group compared to the tacrolimus capsule group and were similar in both treatment groups from Day 10 to Week 3. Thereafter, tacrolimus doses were, on average, 10% to 20% lower for ENVARSUS XR than in the tacrolimus capsule group.

Tacrolimus whole blood trough concentrations were monitored on Days 2, 3, 4, 7, 10, 14, 21, 30, 45, 60, 90, 120, 180,270, and 360. On Day 2 predose, the proportion of patients in the ENVARSUS XR group with tacrolimus troughconcentration that were within, above and below the target tacrolimus trough concentration range of 6 to 11 ng/mL was33%, 39%, and 28%, respectively, compared to 27%, 12%, and 61%, in the tacrolimus [immediate release] capsule group.The average tacrolimus trough concentrations (per local laboratory reading) for the ENVARSUS XR group were abovethe target range during the first week post-transplant, and higher than in the tacrolimus capsule group during the first 2weeks post-transplant (see Figure 1). Thereafter, the mean tacrolimus trough concentrations were similar between thetreatment groups.

                                     Figure 1. Study 1 Tacrolimus Trough Concentrations by Treatment Group and Visits

Concomitant Immunosuppressive Drugs

In Study 1, the concomitant use of mycophenolate products was comparable between the ENVARSUS XR and tacrolimus[immediate-release] capsule treatment groups. Patients in both groups started MMF at an average dose of 1 gram twicedaily. The MMF daily dose was reduced to less than 2 grams over the course of the study; the mean MMF equivalent totaldaily dose was approximately 1.5 grams at Month 12 in both treatment groups. Likewise, the average doses ofcorticosteroids were comparable between the two treatment groups throughout the 12-month study period. Majority (96%ENVARSUS XR and 99% tacrolimus [immediate-release] capsules) of the patients received two 20 mg doses ofbasiliximab for antibody induction.

Efficacy Results

The efficacy failure rates including patients who developed biopsy-proven acute rejection (BPAR), graft failure, death,and/or lost to follow-up at 12 months, as well as the rates of the individual events, are shown by treatment group inTable 10 for the intent-to-treat population.

Table 10. Incidence of BPAR, Graft Loss, Death or Lost to Follow-up at 12 Months in De Novo Kidney Transplant Patients in Study 1

Glomerular Filtration Rates

Renal function was assessed as change from Day 30 (baseline) by eGFR calculated using the MDRD7 equation. BaselineeGFR values were 53.8 ml/min/1.73 m2 and 54.4 ml/min/1.73 m2, and 12 month eGFR values were 58.6 ml/min/1.73 m2and 59.8 ml/min/1.73 m2 in the ENVARSUS XR and the tacrolimus [immediate-release] capsule groups, respectively,maintaining the small difference of approximately 1ml/min/1.73 m2 between the treatment groups.

Study 2

Study 2 (NCT 00765661) was an open-label Phase 2 study conducted in de novo kidney transplant patients randomized toonce daily ENVARSUS XR (N=32) or twice daily tacrolimus [immediate-release] capsule(N=31). The study wasconducted in the US and patients received an organ from a deceased or living donor. Pharmacokinetics were evaluatedduring the first 2 weeks with an additional 50-week treatment and follow-up to evaluate safety and efficacy.

Study 2 did not have any exclusion criteria based on cardiac disease or ECG findings but patients who received a kidneyfrom a non-heart-beating donor or with cold ischemia time ≥ 36 hours were excluded. Patients were randomized within 12hours after transplantation and received the first dose of the study drug within 48 hours of graft reperfusion. Inductiontreatment and concomitant immunosuppressive therapy were allowed per center-specific practices.

The mean age of study population was 47 years (range 23-69); 68% were male; 75% were Caucasian, 21% were African-American, 5% were Asian. Two patients in each group withdrew early from the study due to adverse events.

Tacrolimus Therapy

In Study 2, de novo kidney transplant patients received a starting dosage of 0.14 mg/kg/day (given once daily) for ENVARSUS XR and 0.20 mg/kg/day (given twice daily) for tacrolimus [immediate-release] capsule. On Day 2 predose, the proportion of patients in the ENVARSUS XR group with tacrolimus trough concentration that were within, above, andbelow 6 to 11 ng/mL was 53%, 11%, and 37%, respectively. In Study 1, the proportion of de novo kidney transplantpatients receiving a starting dose of 0.1 mg/kg/day of tacrolimus capsules that were within, above, and below 6 to 11ng/mL on Day 2 predose was 27%, 12%, and 61%, respectively.

Concomitant Immunosuppressive Drugs

In Study 2, concomitant therapy with mycophenolate products or azathioprine, corticosteroids, and antibody inductionwas permitted but not required. The mean daily MMF, prednisone, and antibody induction doses were similar between theENVARSUS XR and tacrolimus capsules treatment groups.

Efficacy

There were no deaths or graft failures in Study 2. Acute rejection rates at 12 months were 3.1% (1/32) in the ENVARSUSXR group and 6.5% (2/31) in the tacrolimus capsules group and 2 patients (one in each group) were lost to follow-up.

Conversion Study from Tacrolimus Capsules in Stable Kidney Transplant Recipients

Study 3

The conversion study, Study 3 (NCT00817206), was a Phase 3 randomized, open-label, multinational study evaluating once daily ENVARSUS XR when used to replace tacrolimus [immediate-release] capsules administered twice daily for maintenance immunosuppression to prevent acute allograft rejection in stable adult kidney transplant patients. Patients who received a kidney transplant 3 months to 5 years before study entry and on a stable dose of tacrolimus [immediate-release] capsules of at least 2 mg per day and tacrolimus whole blood trough concentrations between 4 and 15 ng/mL were randomized to 1) switch from twice daily tacrolimus capsules to once daily ENVARSUS XR (N=163) or 2) continue tacrolimus capsules twice daily (N=163). MMF or mycophenolate sodium (MPS), or azathioprine (AZA) and/or corticosteroids were allowed as concomitant immunosuppressants during the study period according to the standard of care at the participating site.

The mean age of study population was 50 years; 67% were male; 73% were Caucasian, 22% were African-American, 2% were Asian and 3% were categorized as other races. Living donors provided 35% of the organs and 65% of patients received a kidney transplant from a deceased donor. Premature discontinuation from treatment at the end of one year occurred in 13% of ENVARSUS XR patients and 6% of tacrolimus capsule patients.

Tacrolimus Therapy

In Study 3, stable kidney transplant patients converted to ENVARSUS XR at an average daily dose that was 80% of their tacrolimus [immediate-release] capsules daily dose prior to conversion. Mean tacrolimus whole blood trough concentrations were maintained within a relatively narrow range throughout the duration of the study for both the ENVARSUS XR conversion group and the tacrolimus capsules continuation group. At Week 1 (after 7 days of stable dosing), the mean ± SD tacrolimus trough concentrations were 7.2 ± 3.1 ng/mL for the ENVARSUS XR conversion group and 7.7 ± 2.5 for the tacrolimus capsules continuation group; the baseline values were 7.8 ± 2.3, and 8.0 ± 2.3, respectively.

MMF Therapy

In Study 3, the average daily mycophenolate equivalent doses were comparable between the ENVARSUS XR andtacrolimus capsules treatment groups.

Efficacy Results

The efficacy failure rates including patients who developed BPAR, graft failure, death, and/or lost to follow-up at 12 months, as well as the rates of the individual events, are shown by treatment group in Table 11 for the modified intent-to-treat population.

Glomerular Filtration Rates

The mean estimated glomerular filtration rates (eGFR), using the Modification of Diet in Renal Disease 7 (MDRD7) formula, were 61.5 ml/min/1.73 m2 and 60.0 ml/min/1.73 m2 at baseline (Day 0) and 62.0 ml/min/1.73 m2 and 61.4 ml/min/1.73 m2 at 12 months in the ENVARSUS XR and tacrolimus capsules treatment groups, respectively.